# Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

> **NCT06739395** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Solid Tumor
- Precision Medicine

## Interventions

- **DRUG:** Olaparib tablet
- **DRUG:** Temozolomide capsule
- **DRUG:** Anlotinib
- **DRUG:** Trametinib tablet
- **DRUG:** Dabrafenib
- **DRUG:** Vebreltinib Enteric Capsules
- **DRUG:** Alpelisib Pill
- **DRUG:** Sacituzumab Govitecan-Hziy 180 MG
- **DRUG:** Lenvatinib Capsules
- **DRUG:** Pazopanib Pill
- **DRUG:** Palbociclib Pill
- **DRUG:** Chidamide
- **DRUG:** PD-1/PD-L1/PD-1&CTLA4 inhibitor
- **DRUG:** Target Gene

## Key facts

- **NCT ID:** NCT06739395
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-05-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06739395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06739395, "Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06739395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*